- Home
- CING vs SONN Comparison
CING vs SONN Comparison
Compare CING & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- SONN
- Stock Information
- Founded
- CING 2012
- SONN N/A
- Country
- CING United States
- SONN United States
- Employees
- CING N/A
- SONN N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CING Health Care
- SONN Health Care
- Exchange
- CING Nasdaq
- SONN Nasdaq
- Market Cap
- CING 22.9M
- SONN 21.4M
- IPO Year
- CING 2021
- SONN N/A
- Fundamental
- Price
- CING N/A
- SONN $5.00
- Analyst Decision
- CING Strong Buy
- SONN Strong Buy
- Analyst Count
- CING 4
- SONN 1
- Target Price
- CING $31.00
- SONN $20.00
- AVG Volume (30 Days)
- CING 160.4K
- SONN 1.6M
- Earning Date
- CING 11-06-2025
- SONN 08-13-2025
- Dividend Yield
- CING N/A
- SONN N/A
- EPS Growth
- CING N/A
- SONN N/A
- EPS
- CING N/A
- SONN N/A
- Revenue
- CING N/A
- SONN $1,000,000.00
- Revenue This Year
- CING N/A
- SONN $5,376.22
- Revenue Next Year
- CING N/A
- SONN N/A
- P/E Ratio
- CING N/A
- SONN N/A
- Revenue Growth
- CING N/A
- SONN 1689.52
- 52 Week Low
- CING $3.02
- SONN $1.08
- 52 Week High
- CING $6.01
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- CING 53.04
- SONN 51.69
- Support Level
- CING $3.91
- SONN $4.90
- Resistance Level
- CING $4.24
- SONN $6.15
- Average True Range (ATR)
- CING 0.21
- SONN 0.77
- MACD
- CING 0.06
- SONN -0.13
- Stochastic Oscillator
- CING 79.18
- SONN 31.33
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.